Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.13199
Abstract: To evaluate the 2‐year retention rate of golimumab compared with etanercept and adalimumab as second‐line biologic agent in rheumatoid arthritis (RA) patients who failed a previous tumor necrosis factor inhibitor (TNFi). read more here.
Keywords: agent rheumatoid; line biologic; rheumatoid arthritis; tumor necrosis ... See more keywords